Expression of EMP1, EMP2, and EMP3 in breast phyllodes tumors.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): Cha YJ;Cha YJ; Koo JS; Koo JS
  • Source:
    PloS one [PLoS One] 2020 Aug 28; Vol. 15 (8), pp. e0238466. Date of Electronic Publication: 2020 Aug 28 (Print Publication: 2020).
  • Publication Type:
    Journal Article; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Breast Neoplasms/*metabolism ; Membrane Glycoproteins/*metabolism ; Neoplasm Proteins/*metabolism ; Phyllodes Tumor/*metabolism ; Receptors, Cell Surface/*metabolism; Adult ; Biomarkers, Tumor/metabolism ; Breast Neoplasms/pathology ; Humans ; Immunohistochemistry ; Middle Aged ; Neoplasm Grading ; Phyllodes Tumor/pathology ; Prognosis ; Stromal Cells/metabolism ; Stromal Cells/pathology ; Survival Analysis ; Tissue Array Analysis
    • Abstract:
      Purpose: Phyllodes tumors (PTs) are biphasic tumors accounting for 0.3-1.5% of all breast tumors. Epithelial membrane proteins (EMPs) have been reported in various malignant tumors but their expression in PTs is unclear. In this study, we aimed to evaluate the expression of EMP1, EMP2, and EMP3 in breast phyllodes tumors (PTs), and to investigate their clinical implications.
      Methods: In total, 185 PTs were used for constructing a tissue microarray. Immunohistochemical staining for EMP1, EMP2, and EMP3 was performed, and the results were analyzed along with the clinicopathologic parameters.
      Results: In total, 185 PTs were included in this study, and comprised 138 benign, 32 borderline, and 15 malignant PTs. In malignant PTs, the epithelial component showed decreased expression of EMP1 (P = 0.027), EMP2 (P = 0.004), and EMP3 (P = 0.032), compared to the benign and borderline PTs. Conversely, stromal component of borderline and malignant PTs showed higher expression of EMP1 (P = 0.027), EMP2 (P = 0.004), and EMP3 (P = 0.032) compared to benign PTs. Expression of EMP1 and EMP3 correlated positively with stromal cellularity and cellular atypia (P < 0.001). In the univariate analysis, stromal EMP3 was associated with shorter disease-free survival (P < 0.001), and shorter overall survival (P = 0.034).
      Conclusion: The expression of EMP1, EMP2, and EMP3 is decreased in the epithelial component and is increased in the stromal component of PT with higher histologic grade. Thus, stromal EMP3 expression may serve as an independent prognostic factor in PT.
      Competing Interests: The authors have declared that no competing interests exist.
    • References:
      Tumour Biol. 2012 Jun;33(3):787-98. (PMID: 22203494)
      Br J Cancer. 2015 Oct 20;113(8):1244-8. (PMID: 26355235)
      Tumour Biol. 2017 Jul;39(7):1010428317718404. (PMID: 28718375)
      Breast Cancer Res Treat. 2015 Jul;152(2):305-12. (PMID: 26093648)
      Gene. 1996 Dec 12;183(1-2):69-75. (PMID: 8996089)
      Mol Cancer Res. 2015 Apr;13(4):613-9. (PMID: 25593300)
      J Clin Pathol. 2018 Feb;71(2):125-128. (PMID: 28751520)
      Cancer Res. 2005 Apr 1;65(7):2565-71. (PMID: 15805250)
      PLoS One. 2011;6(5):e19945. (PMID: 21637765)
      Expert Opin Ther Targets. 2013 Jul;17(7):743-60. (PMID: 23651053)
      Oncotarget. 2017 Feb 28;8(9):14343-14358. (PMID: 27527869)
      Mol Cancer Ther. 2014 Apr;13(4):902-15. (PMID: 24448822)
      Semin Cancer Biol. 2012 Oct;22(5-6):455-61. (PMID: 22627188)
      Cancer Res. 2005 Oct 1;65(19):8679-89. (PMID: 16204036)
      Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):199-211. (PMID: 28408326)
      Genes Chromosomes Cancer. 2015 Jul;54(7):444-52. (PMID: 25931199)
      Cancer Res. 1993 Sep 1;53(17):4071-4. (PMID: 8395336)
      Breast J. 2014 Nov-Dec;20(6):639-44. (PMID: 25227987)
      Hum Pathol. 2000 Oct;31(10):1214-22. (PMID: 11070114)
      Hum Pathol. 2010 Jan;41(1):107-12. (PMID: 19762066)
      Expert Opin Ther Targets. 2009 Jul;13(7):811-22. (PMID: 19466912)
      J Huazhong Univ Sci Technolog Med Sci. 2012 Dec;32(6):834-838. (PMID: 23271282)
      J Biol Chem. 2014 May 16;289(20):13974-85. (PMID: 24644285)
      J Pathol. 2019 Dec;249(4):447-460. (PMID: 31411343)
      J Pathol. 2003 Aug;200(5):627-32. (PMID: 12898599)
      J Pathol. 2016 Mar;238(4):508-18. (PMID: 26832993)
      Curr Opin Oncol. 2013 Jan;25(1):76-84. (PMID: 23197193)
      Cancer Res. 2003 Nov 15;63(22):7791-8. (PMID: 14633705)
      BMC Cancer. 2019 Apr 23;19(1):372. (PMID: 31014268)
      Oncotarget. 2015 Oct 27;6(33):34859-74. (PMID: 26472188)
      Nat Genet. 2015 Nov;47(11):1341-5. (PMID: 26437033)
      Tumour Biol. 2014 Apr;35(4):3185-93. (PMID: 24292952)
      J Pathol. 2002 Apr;196(4):437-44. (PMID: 11920740)
      Tumour Biol. 2014 Apr;35(4):3347-54. (PMID: 24402572)
      Genomics. 1998 May 1;49(3):443-7. (PMID: 9615230)
      Nat Genet. 2014 Aug;46(8):877-80. (PMID: 25038752)
    • Accession Number:
      0 (Biomarkers, Tumor)
      0 (EMP2 protein, human)
      0 (EMP3 protein, human)
      0 (Membrane Glycoproteins)
      0 (Neoplasm Proteins)
      0 (Receptors, Cell Surface)
      0 (epithelial membrane protein-1)
    • Publication Date:
      Date Created: 20200829 Date Completed: 20201019 Latest Revision: 20201019
    • Publication Date:
      20240105
    • Accession Number:
      PMC7454950
    • Accession Number:
      10.1371/journal.pone.0238466
    • Accession Number:
      32857809